LX1 Targets Androgen Receptor Variants and AKR1C3 to overcome Therapy Resistance in Advanced Prostate Cancer

Investigators designed, synthesized, and characterized a class of LX compounds targeting both androgen receptor (AR)/AR variants and AKR1C3.